Ocugen Inc
OCGN1.400USD
+0.080+6.06%
終値 09/18, 16:00（ET）15分遅れの株価
409.07M時価総額
損失額直近12ヶ月PER
詳細情報 Ocugen Inc 企業名
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
企業情報
企業コードOCGN
会社名Ocugen Inc
上場日Dec 03, 2014
最高経営責任者「CEO」Dr. Shankar Musunuri, Ph.D.
従業員数95
証券種類Ordinary Share
決算期末Dec 03
本社所在地11 Great Valley Parkway
都市MALVERN
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号19355
電話番号14843284701
ウェブサイトhttps://ocugen.com/
企業コードOCGN
上場日Dec 03, 2014
最高経営責任者「CEO」Dr. Shankar Musunuri, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+0.01%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+250.87%
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
75.00K
+50.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
--
Ms. Tiffany Hamilton
Ms. Tiffany Hamilton
Head of Communications
Head of Communications
--
--
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Huma Qamar, M.D.
Dr. Huma Qamar, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+0.01%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+250.87%
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
75.00K
+50.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
--
Ms. Tiffany Hamilton
Ms. Tiffany Hamilton
Head of Communications
Head of Communications
--
--
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
収益内訳
FY2025Q1
FY2024
FY2023
FY2021
FY2020
データなし
地域別USD
会社名
収益
比率
United States
1.48M
0.00%
事業別
地域別
データなし
株主
更新時刻: Tue, Aug 19
更新時刻: Tue, Aug 19
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
4.73%
BlackRock Institutional Trust Company, N.A.
1.66%
Millennium Management LLC
1.62%
GMT Capital Corp.
1.33%
Geode Capital Management, L.L.C.
1.12%
他の
89.54%
株主統計
株主統計
比率
The Vanguard Group, Inc.
4.73%
BlackRock Institutional Trust Company, N.A.
1.66%
Millennium Management LLC
1.62%
GMT Capital Corp.
1.33%
Geode Capital Management, L.L.C.
1.12%
他の
89.54%
種類
株主統計
比率
Investment Advisor
8.16%
Hedge Fund
4.87%
Investment Advisor/Hedge Fund
2.46%
Individual Investor
1.13%
Research Firm
1.00%
Corporation
0.37%
Bank and Trust
0.08%
Venture Capital
0.07%
他の
81.87%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
268
78.45M
26.84%
-13.23M
2025Q1
278
81.07M
27.89%
-11.63M
2024Q4
292
76.62M
26.34%
-21.25M
2024Q3
306
84.66M
29.43%
-6.14M
2024Q2
300
72.04M
27.84%
+19.28M
2024Q1
302
36.88M
14.47%
-15.26M
2023Q4
300
30.54M
12.06%
-31.79M
2023Q3
314
37.28M
14.69%
-34.75M
2023Q2
332
53.23M
20.91%
-28.29M
2023Q1
336
68.93M
30.49%
-36.35M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
16.68M
5.71%
+64.02K
+0.39%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
18.22M
6.24%
-377.91K
-2.03%
Mar 31, 2025
GMT Capital Corp.
4.15M
1.42%
+1.70M
+69.20%
Mar 31, 2025
Geode Capital Management, L.L.C.
6.89M
2.36%
+300.41K
+4.56%
Mar 31, 2025
GSA Capital Partners LLP
1.64M
0.56%
+492.30K
+42.97%
Mar 31, 2025
Musunuri (Shankar Ph.D)
1.34M
0.46%
+607.32K
+82.50%
Apr 14, 2025
State Street Global Advisors (US)
5.93M
2.03%
+65.93K
+1.12%
Mar 31, 2025
Illumination Wealth Management
1.16M
0.4%
+1.16M
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Tue, Sep 2
更新時刻: Tue, Sep 2
銘柄名
比率
Invesco NASDAQ Future Gen 200 ETF
0.56%
Pacer WealthShield ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
詳細を見る
Invesco NASDAQ Future Gen 200 ETF
比率0.56%
Pacer WealthShield ETF
比率0%
iShares Russell 2000 ETF
比率0%
iShares Micro-Cap ETF
比率0%
ProShares UltraPro Russell2000
比率0%
ProShares Hedge Replication ETF
比率0%
iShares Core S&P Total U.S. Stock Market ETF
比率0%
iShares Russell 2000 Growth ETF
比率0%
Global X Russell 2000 ETF
比率0%
Proshares Ultra Russell 2000
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
